Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMOEARH)

Drug Name

AZD2014 Drug Info

Synonyms

AZD2014; 1009298-59-2; Vistusertib; AZD-2014; AZD 2014; UNII-0BSC3P4H5X; 0BSC3P4H5X; cc-551; 3-[2,4-Bis((3S)-3-methylmorpholin-4-yl)pyrido[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; CHEMBL2336325; 3-[2,4-Bis((3S)-3-methyLmorpholin-4-yl)pyrido-[5,6-e]pyrimidin-7-yl]-N-methylbenzamide; C25H30N6O3; 3-(2,4-bis((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide; 3-[2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl]-N-methylbenzamide; Vistusertib [INN]; Vistusertib [USAN]; Vistusertib (JAN/INN)

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]

Cross-matching ID

PubChem CID: 25262792
CAS Number: CAS 1009298-59-2
TTD Drug ID: DMOEARH
INTEDE Drug ID: DR1837

Molecule-Related Drug Atlas

Molecule Type:

DTT

DME

DOT

Drug Status:

Clinical Trial Drug(s)

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Mammalian target of rapamycin complex 1 (mTORC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RBT-101	DMDZW8K	Respiratory tract infection	CA45	Phase 3	[6]
ME-344	DM6JN19	Breast cancer	2C60-2C65	Phase 1/2	[2]
VS-5584	DMMO3G5	Malignant mesothelioma	2C26.0	Phase 1	[7]
Palomid-529	DM428Y3	Alzheimer disease	8A20	Phase 1	[8]
NV-5138	DMLKS7W	Major depressive disorder	6A70.3	Phase 1	[9]
------------------------------------------------------------------------------------

Drug(s) Targeting Serine/threonine-protein kinase mTOR (mTOR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sirolimus	DMGW1ID	Advanced cancer	2A00-2F9Z	Approved	[10]
Temsirolimus	DMS104F	Renal cell carcinoma	2C90	Approved	[11]
PF-04449913	DMSB068	Chronic myelomonocytic leukaemia	2A40	Approved	[12]
Everolimus	DM8X2EH	Advanced cancer	2A00-2F9Z	Approved	[13]
Novolimus	DM6ZPLQ	Artery stenosis	BD52	Approved	[14]
Zotarolimus	DMRMCXW	Solid tumour/cancer	2A00-2F9Z	Approved	[15]
Ridaforolimus	DMLHEU7	Sarcoma	2A60-2C35	Phase 3	[16]
MM-141	DM2RJ4D	Pancreatic cancer	2C10	Phase 2	[2]
PQR309	DMMCYZ8	Squamous head and neck cell carcinom	2D60.0	Phase 2	[14]
Salirasib	DMRSU4X	Lung cancer	2C25.0	Phase 2	[14]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Target of rapamycin complex 2 MAPKAP1 (MTORC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ME-344	DM6JN19	Breast cancer	2C60-2C65	Phase 1/2	[2]
VS-5584	DMMO3G5	Malignant mesothelioma	2C26.0	Phase 1	[7]
Palomid-529	DM428Y3	Alzheimer disease	8A20	Phase 1	[8]
------------------------------------------------------------------------------------

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[17]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[18]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[19]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[20]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[21]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[22]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[23]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[24]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[18]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[25]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[26]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[27]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[28]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[29]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[30]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[31]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[32]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[33]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[34]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[29]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 2C8 (CYP2C8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[35]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[36]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[36]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[37]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[38]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[39]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[40]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[36]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[41]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[42]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By RAC-alpha serine/threonine-protein kinase (AKT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Capivasertib	DM9SKW8	Breast cancer	2C60-2C65	Approved	[5]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[43]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[44]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[45]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[46]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[47]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[48]
Selenium	DM25CGV	N. A.	N. A.	Approved	[49]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[50]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[51]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Sterol regulatory element-binding protein 1 (SREBF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[52]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[53]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[54]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[55]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[56]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[57]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[58]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[59]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[60]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[61]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Small ribosomal subunit protein eS6 (RPS6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[62]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[63]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[64]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[65]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[66]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[67]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[68]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[69]
Capivasertib	DM9SKW8	Breast cancer	2C60-2C65	Approved	[5]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[70]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Sequestosome-1 (SQSTM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[71]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[72]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[73]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[74]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[75]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[76]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[77]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[58]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[52]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[78]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[72]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[79]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[77]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[58]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[80]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[81]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[82]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[83]
Trovafloxacin	DM6AN32	Acute gonococcal cervicitis		Approved	[84]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[85]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Mammalian target of rapamycin complex 1 (mTORC1)	TTX4GLS	MTOR_HUMAN-RPTOR_HUMAN-LST8_HUMAN-AKTS1_HUMAN-DPTOR_HUMAN	Inhibitor	[2]
Serine/threonine-protein kinase mTOR (mTOR)	TTCJG29	MTOR_HUMAN	Inhibitor	[3]
Target of rapamycin complex 2 MAPKAP1 (MTORC2)	TTWDKCL	SIN1_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[4]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[4]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[4]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B)	OTUYHB84	MLP3B_HUMAN	Gene/Protein Processing	[5]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Post-Translational Modifications	[5]
Sequestosome-1 (SQSTM1)	OTGY5D5J	SQSTM_HUMAN	Gene/Protein Processing	[5]
Small ribosomal subunit protein eS6 (RPS6)	OTT4D1LN	RS6_HUMAN	Post-Translational Modifications	[5]
Sterol regulatory element-binding protein 1 (SREBF1)	OTWBRPAI	SRBP1_HUMAN	Gene/Protein Processing	[5]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7699).
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem Biophys Res Commun. 2014 Jan 10;443(2):406-12.
4	First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014. Clin Cancer Res. 2015 Aug 1;21(15):3412-9.
5	Inhibition of cholesterol metabolism underlies synergy between mTOR pathway inhibition and chloroquine in bladder cancer cells. Oncogene. 2016 Aug 25;35(34):4518-28. doi: 10.1038/onc.2015.511. Epub 2016 Feb 8.
6	Constrained peptides' time to shine. Nat Rev Drug Discov. 2018 Jul 30;17(8):531-533.
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2. Int J Cancer. 2013 Sep 1;133(5):1222-33.
9	Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation. J Clin Invest. 2019 Apr 16;129(6):2542-2554.
10	Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
11	Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20.
12	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
13	Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9.
14	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109).
15	Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep. 2008 Jun;25(3):475-516.
16	A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
17	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
18	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
19	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
20	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
21	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
22	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
23	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
24	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
25	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
26	Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
27	Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
28	Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
29	Drug Interactions Flockhart Table
30	Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
31	Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
32	Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
33	Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
34	Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
35	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
36	Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
37	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
38	Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
39	Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
40	Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
41	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
42	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
43	Nicotine-induced survival signaling in lung cancer cells is dependent on their p53 status while its down-regulation by curcumin is independent. Mol Cancer. 2010 Aug 20;9:220.
44	Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
45	-Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
46	Dihydromyricetin suppresses tumor growth via downregulation of the EGFR/Akt/survivin signaling pathway. J Biochem Mol Toxicol. 2023 Jun;37(6):e23328. doi: 10.1002/jbt.23328. Epub 2023 Feb 19.
47	Oxidative stress induces parallel autophagy and mitochondria dysfunction in human glioma U251 cells. Toxicol Sci. 2009 Aug;110(2):376-88. doi: 10.1093/toxsci/kfp101. Epub 2009 May 18.
48	Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver Int. 2015 Mar;35(3):1063-76. doi: 10.1111/liv.12626. Epub 2014 Jul 30.
49	Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
50	Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
51	Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem Mol Toxicol. 2018 Jan;32(1). doi: 10.1002/jbt.22007. Epub 2017 Nov 7.
52	Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
53	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
54	Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
55	Poly(ADP-Ribose) Polymerase Inhibitor PJ34 Attenuated Hepatic Triglyceride Accumulation in Alcoholic Fatty Liver Disease in Mice. J Pharmacol Exp Ther. 2018 Mar;364(3):452-461. doi: 10.1124/jpet.117.243105. Epub 2018 Jan 9.
56	Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
57	Delta5 desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPARalpha, in THP-1 cells. Eur J Pharmacol. 2007 Oct 1;571(2-3):97-105.
58	Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
59	Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
60	Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
61	Inhibition of liver x receptor/retinoid X receptor-mediated transcription contributes to the proatherogenic effects of arsenic in macrophages in vitro. Arterioscler Thromb Vasc Biol. 2010 Jun;30(6):1228-36. doi: 10.1161/ATVBAHA.110.205500. Epub 2010 Mar 25.
62	Cannabidiol Reduces Leukemic Cell Size - But Is It Important?. Front Pharmacol. 2017 Mar 24;8:144. doi: 10.3389/fphar.2017.00144. eCollection 2017.
63	Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
64	Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des. 2011 Dec;78(6):999-1005. doi: 10.1111/j.1747-0285.2011.01239.x. Epub 2011 Oct 31.
65	D-glucosamine down-regulates HIF-1alpha through inhibition of protein translation in DU145 prostate cancer cells. Biochem Biophys Res Commun. 2009 Apr 24;382(1):96-101. doi: 10.1016/j.bbrc.2009.02.129. Epub 2009 Feb 28.
66	Proteomics-based identification of differentially abundant proteins from human keratinocytes exposed to arsenic trioxide. J Proteomics Bioinform. 2014 Jul;7(7):166-178.
67	Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling. Aging (Albany NY). 2012 Dec;4(12):952-65. doi: 10.18632/aging.100521.
68	Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival. Anticancer Res. 2010 Oct;30(10):3895-901.
69	Imatinib disturbs lysosomal function and morphology and impairs the activity of mTORC1 in human hepatocyte cell lines. Food Chem Toxicol. 2022 Apr;162:112869. doi: 10.1016/j.fct.2022.112869. Epub 2022 Feb 16.
70	Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
71	Transcriptomic Analysis of Stem Cells Treated with Moringin or Cannabidiol: Analogies and Differences in Inflammation Pathways. Int J Mol Sci. 2019 Nov 30;20(23):6039. doi: 10.3390/ijms20236039.
72	Antidepressant drug sertraline modulates AMPK-MTOR signaling-mediated autophagy via targeting mitochondrial VDAC1 protein. Autophagy. 2021 Oct;17(10):2783-2799. doi: 10.1080/15548627.2020.1841953. Epub 2020 Nov 9.
73	Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells. Clin Lung Cancer. 2015 Sep;16(5):e55-66. doi: 10.1016/j.cllc.2015.03.006. Epub 2015 Apr 2.
74	MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
75	Harnessing autophagy to overcome mitogen-activated protein kinase kinase inhibitor-induced resistance in metastatic melanoma. Br J Dermatol. 2019 Feb;180(2):346-356. doi: 10.1111/bjd.17333. Epub 2018 Nov 25.
76	Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
77	Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
78	Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
79	Repression of Kisspeptin1 weakens hydrogen peroxide-caused injury in HTR8 cells via adjusting PI3K/AKT/mTOR pathway. J Biochem Mol Toxicol. 2020 May;34(5):e22461. doi: 10.1002/jbt.22461. Epub 2020 Feb 11.
80	Low Autophagy (ATG) Gene Expression Is Associated with an Immature AML Blast Cell Phenotype and Can Be Restored during AML Differentiation Therapy. Oxid Med Cell Longev. 2018 Mar 18;2018:1482795. doi: 10.1155/2018/1482795. eCollection 2018.
81	Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
82	Inhibitory effect of PXR on ammonia-induced hepatocyte autophagy via P53. Toxicol Lett. 2018 Oct 1;295:153-161. doi: 10.1016/j.toxlet.2018.06.1066. Epub 2018 Jun 14.
83	Arsenic trioxide induces autophagic cell death in osteosarcoma cells via the ROS-TFEB signaling pathway. Biochem Biophys Res Commun. 2018 Jan 29;496(1):167-175. doi: 10.1016/j.bbrc.2018.01.018. Epub 2018 Jan 4.
84	TNF enhances trovafloxacin-induced in vitro hepatotoxicity by inhibiting protective autophagy. Toxicol Lett. 2021 May 15;342:73-84. doi: 10.1016/j.toxlet.2021.02.009. Epub 2021 Feb 17.
85	Hydroquinone-induced endoplasmic reticulum stress affects TK6 cell autophagy and apoptosis via ATF6-mTOR. Environ Toxicol. 2023 Aug;38(8):1874-1890. doi: 10.1002/tox.23814. Epub 2023 May 6.